ClinicalTrials.gg
CompletedNCT02210247Updated Jul 6, 2021Results posted

Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers

A Phase 1 interventional study of EXPAREL in Healthy Volunteers, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and pharmacokinetics of redosing EXPAREL via local subcutaneous infiltration in healthy volunteers.

Read the detailed description

During Dosing Period 1, blood samples for pharmacokinetic (PK) analysis will be obtained predose (15 minutes prior to administration of EXPAREL) through 12 hours postdose (i.e., at 15 and 30 minutes, 1, 2, 4, 8, and 12 hours) for Cohort 4; through 36 hours postdose (i.e., at 15 and 30 minutes, 1, 2, 4, 8, 12, 24, and 36 hours) for Cohort 3; through 60 hours postdose (i.e., at 15 and 30 minutes, 1, 2, 4, 8, 12, 24, 36, 48, and 60 hours) for Cohort 2; and through 72 hours postdose (i.e., at 15 and 30 minutes, 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours) for Cohorts 1 and 5.

During Dosing Period 2 (Cohorts 2, 3, and 4 only), blood samples for PK analysis will be obtained predose (15 minutes prior to administration of EXPAREL) through 72 hours postdose (i.e., at 15 and 30 minutes, 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 hours).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ≥18 years of age.
  • (ASA) physical status 1 or 2.
  • Female subjects must be surgically sterile, at least 2 years , or using a medically acceptable method of . If of , must have a documented negative pregnancy test within 24 hours before the first study drug administration.
  • Able to provide , adhere to the study visit schedule, and complete all study assessments.

Exclusion criteria

Exclusion Criteria:

  • History of or idiosyncratic reactions to amide-type local anesthetics.
  • History of abnormal bleeding tendencies/clotting disorders.
  • Regular use of anticoagulants (except for low dose aspirin for cardioprotection).
  • Received any drug within 30 days prior to study drug administration, and/or has planned administration of another investigational product or procedure during his/her participation in this study.
  • Currently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration.
  • Subjects with significant medical conditions or laboratory results that, in the opinion of the Investigator, would constitute a to participation in the study, or cause inability to comply with the study requirements.
  • Received bupivacaine or other local anesthetic within 7 days of first study drug administration.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Cohort 1

    Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.

    Drug: EXPAREL

  • Active comparator
    Cohort 2

    Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.

    Drug: EXPAREL

  • Active comparator
    Cohort 3

    Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.

    Drug: EXPAREL

  • Active comparator
    Cohort 4

    Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.

    Drug: EXPAREL

  • Active comparator
    Cohort 5

    Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).

    Drug: EXPAREL

Interventions

  • Also known as: bupivacaine liposome injectable suspension

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: Period(P)1 all cohorts (C) 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects

  2. Time to Maximum Concentration (Tmax)

    Time frame: Period(P)1 all cohorts 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects

  3. Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC(0-last)]

    Time frame: Period(P)1 all cohorts (C) 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects

  4. Apparent Terminal Elimination Half-life

    Time frame: Period(P)1 all cohorts 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects

  5. The Apparent Terminal Elimination Rate Constant (λz)

    Time frame: Period(P)1 all cohorts 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects

07

Results

Posted Jul 2, 2021

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Started1212121212
Completed1212121212
Not completed00000

Outcome measures

PrimaryMaximum Plasma Concentration (Cmax)
Time frame:
Period(P)1 all cohorts (C) 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax)
ng/mLCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Maximum Plasma Concentration (Cmax)129 ± 47207 ± 57202 ± 74290 ± 119246 ± 78
PrimaryTime to Maximum Concentration (Tmax)
Time frame:
Period(P)1 all cohorts 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects
Reported as:
Median · hours
Time to Maximum Concentration (Tmax)
hoursCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Time to Maximum Concentration (Tmax)24 (24 to 72)48 (24 to 72)48 (1 to 72)36 (24 to 72)24 (8 to 72)
PrimaryArea Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC(0-last)]
Time frame:
Period(P)1 all cohorts (C) 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects
Reported as:
Mean · H*ng/mL
Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC(0-last)]
H*ng/mLCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Concentration [AUC(0-last)]5917 ± 173810976 ± 287910201 ± 372115227 ± 746311567 ± 3737
PrimaryApparent Terminal Elimination Half-life
Time frame:
Period(P)1 all cohorts 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects
Reported as:
Mean · hours
Apparent Terminal Elimination Half-life
hoursCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
Apparent Terminal Elimination Half-life80.24 ± 22.6444.88 ± 25.6451.70 ± 26.9933.22 ± 3.8059.13 ± 25.03
PrimaryThe Apparent Terminal Elimination Rate Constant (λz)
Time frame:
Period(P)1 all cohorts 15 m in pre, 15,30m, 1,2,34,8,12h postdose. C3: +24, 36 h postdose. C2: C3+48,60h postdose; C1 and C5: C2+72h postdose; P2: C2,3,4 only: 15m pre, 1,2,4,8,12,24,36,48,60,72h postdose. Final at D14- all subjects
Reported as:
Mean · 1/hours
The Apparent Terminal Elimination Rate Constant (λz)
1/hoursCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
The Apparent Terminal Elimination Rate Constant (λz)0.009 ± 0.0030.019 ± 0.0070.016 ± 0.0070.021 ± 0.0020.014 ± 0.006

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1—0/12 (0%)5/12 (41.7%)
Cohort 2—0/12 (0%)2/12 (16.7%)
Cohort 3—0/12 (0%)7/12 (58.3%)
Cohort 4—0/12 (0%)2/12 (16.7%)
Cohort 5—0/12 (0%)3/12 (25%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Cohort 5
HeadacheNervous system disorders3/120/121/120/121/12
Injection-site reactionGeneral disorders0/120/122/120/121/12
Vessel puncture site haematomaGeneral disorders2/120/120/120/120/12
TachycardiaCardiac disorders0/120/120/120/121/12
Abdominal painGastrointestinal disorders0/120/121/120/120/12
DiarrhoeaGastrointestinal disorders0/120/121/120/120/12
NauseaGastrointestinal disorders1/120/120/120/120/12
ToothacheGastrointestinal disorders0/120/121/120/120/12
VomitingGastrointestinal disorders1/120/120/120/120/12
Vaginal infectionInfections and infestations0/120/120/121/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Mean45.6 ± 11.9037.8 ± 11.6636.9 ± 10.8341.6 ± 12.3844.1 ± 14.5641.2 ± 12.39
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Female7028623
Male512104637
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
Hispanic or Latino000000
Not Hispanic or Latino121212121260
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American61099842
White6233418
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4Cohort 5Total
United States121212121260
08

Study locations

1 site
  • Medpace Clinical Pharmacology Unit
    Cincinnati, Ohio 45227, United States
09

References and documents

Publications

  • Rice D, Heil JW, Biernat L. Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers. Clin Drug Investig. 2017 Mar;37(3):249-257. doi: 10.1007/s40261-017-0495-2. PubMed 28120158 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2021, 6 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2014
First posted
Aug 6, 2014
Start
Aug 2014
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Jul 2, 2021
Last update
Jul 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02210247
Responsible party
Sponsor
First posted
Aug 6, 2014
Start date
Aug 2014
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Jul 2, 2021
Last update
Jul 6, 2021

Study contacts

Lukasz Biernat, MD
principal investigator · Medpace Clinical Pharmacology Unit

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion